EP3846854A2 - Improved polypeptide coupled antibiotics - Google Patents
Improved polypeptide coupled antibioticsInfo
- Publication number
- EP3846854A2 EP3846854A2 EP19769720.4A EP19769720A EP3846854A2 EP 3846854 A2 EP3846854 A2 EP 3846854A2 EP 19769720 A EP19769720 A EP 19769720A EP 3846854 A2 EP3846854 A2 EP 3846854A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- och
- seq
- antibiotic
- substituted
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
Definitions
- the present invention relates to an antibiotic comprising at least one polypeptide, wherein the N-termlniis of the polypeptide is not attached to a lipophilic group and preferably the polypeptide is positively charged and comprises optionally a linker connecting the antibiotic and the polypeptide as well as the use of such antibiotics for the treatment of bacterial infections.
- Vancomycin is the pivotal antibiotic for treatment of multi-drug resistant infections, caused by Gram-positive bacteria [5] and is on the WHO list of Essential Medicines [6] Due to the high prevalence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), the use of vancomycin has dramatically increased in past years.
- MRSA methicillin-resistant Staphylococcus aureus
- Vancomycin prevents the stabilization of the bacterial cell wall by inhibiting the cross- linking of peptidoglycan, which is an essential component of the cell wall of Gram-positive bacteria.
- the mechanism of action involves binding to lipid II, which is the precursor of peptidoglycan.
- vancomycin has non-optimal pharmacokinetic properties, which requires 2 to 3 intravenous doses per day. Furthermore, vancomycin has a variable tissue penetration, is slowly bactericidal and shows nephro- and ototoxicity [5].
- VRE vancomycin resistant Enterococci
- Vancomycin resistant Enterococci were first reported in 1988 [11] and several types of resistance genes and mechanisms ⁇ ranging from VanA to VanG, are described [5] The most potent resistance mechanism is VanA, which is also transferable to other species.
- VRSA vancomycin resistant Staphylococcus aureus
- a transferable VanB resistance gene was found in Streptococcus bovis [13].
- the target of vancomycin is the terminal amino acid sequence D-Ala-D-Ala of the peptidoglycan precursor Lipid II muropeptide [7]
- the mechanism of VanA and VanB resistance is the replacement of D-Aia-D-Ala by D-Ala-D-Lac, while VanC resistance results in D-Ala-D- Ser.
- this change in sequence results in a repulsive interaction, which leads to a 1,000 fold lower affinity of vancomycin to Lipid P [14].
- the ribosome targeting drugs linezolid and tigecycline are currently available [5]
- linezolid resistant Enterococci have become more common and have emerged as a serious problem throughout the last years [15].
- lipoglycopeptides oritavancin and dalbavancin Another drawback of the lipoglycopeptides oritavancin and dalbavancin is their extremely long plasma half-life bearing the risk of exposure to sub therapeutic drug levels [17], which enhances the selection of resistant bacteria [18] Furthermore, the new lipoglycopeptides lack activity against isolates containing VanA resistance. These factors limit the use lipoglycopeptides against vancomycin resistant Enterococci. Currently, no bactericidal therapy against VanA Enterococci is approved.
- Figure 1 Membrane staining sites.
- FIG. 2 Biodistribution studies of preferred conjugates a) Biodistribution of a vancomycin- conjugate consisting of a peptide with the sequence yRRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin- V ⁇ -position (corresponding to X 3 of structure (I)) (tested in a single mouse), b) Biodistribution of a vancomycin-conjugate consisting of a peptide with the sequence Myristic acid-RRRyC (SEQ ID NO: 13) coupled with a linker (SMCC) on the vancomycin-V N -position (tested in a single mouse), c) Biodistribution of a vancomycin-conjugate consisting of a peptide with the sequence yRRRRRRC (SEQ ID NO: 10) coupled with a linker (SMPEGg) on the vancomycin-V N -position (tested in a single mouse), d) Biodistribution of
- Figure 3 Scintigraphy of preferred conjugates a) Scintigraphic image of a vancomycin-conjugate consisting of a peptide with the sequence yRRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin-V N -position after 10 min, 30 min, 60 min and 120 min.
- FIG. 4 Preferred conjugation sites of vancomycin A) Preferred conjugation site of vancomycin
- FIG. 1 Animal trials with a sepsis (MRS A systemic infection) model a) Colony foiming units of Staphylococcus aureus USA 300 in the liver of infected mice after 4 days of treatment with either 0.9% NaCl-solution as negative control, vancomycin as positive control and a vancomycin-conjugate consisting of a peptide with the sequence RRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin-V N -position (FU002). b) Weight of the infected mice during the treatment c) Weight loss of the infected mice during the treatment period.
- MRS sepsis
- Figure 6 MIC of preferred modification on different strains.
- Left graph refers to the MIC in pg/ml of a vancomycin-conjugate consisting of a peptide with the sequence RRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin-V N -position (FU002) tested on different strains of Enterococci.
- Right graph refers to the MIC in mol/ml of a vancomycin-conjugate consisting of a peptide with the sequence RRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin- V N -position (FU002) tested on Enterococcus faecium UL602570.
- the level of resistance indicated in the graphs refers to a concentration of an antibiotic which defines whether a species of bacteria is susceptible or resistant to the antibiotic. If the MIC is less than or equal to the level of resistance the bacteria is considered susceptible to the antibiotic. If the MIC is greater than this value the bacteria is considered intermediate or resistant to the antibiotic.
- Figure 7 MIC values of tested conjugation sites of vancomycin. Different variation possibilities of vancomycin describing the l inking position, the used linking method (with ethylene diamine or without) and the coupled peptide.
- R6 Peptide of six arginine residues
- R9 Peptide of nine arginines
- Myr myristyl group
- V c corresponds to Cc
- V R corresponds to X 4
- V N corresponds to X 3
- V v corresponds to X 2.
- FIG. 8 Structure of FU002. Vancomycin-conjugate consisting of a peptide with the sequence
- RRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin-V N - position.
- Figure 9 Comparison of the minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBD) of a vancomycin-conjugate consisting of a peptide with the sequence. RRRRRRRRRC (SEQ ID NO: 16) coupled with a linker (SMCC) on the vancomycin- V ⁇ -position.
- MIC minimal inhibitory concentration
- MBD minimal bactericidal concentration
- Figure 10 Cytotoxic effect of a vancomycin-conjugate consisting of a peptide with the sequence
- RRRRRRC (SEQ ID NO: 10) coupled with a linker (SMCC) on the vancomycin- V N - position on Peripheral Blood Mononuclear cells.
- FIG 11 Structure of a vancomycin derivative with a lipophilic group attached to the N-terminus of a polypeptide, referred to as vancapticin 15.
- Vancapticin 15 is an example of a vancomycin derivative as known from Blaskovich et al. (Nature communications, 2018, 9:22)
- Figure 12 Direct comparison of FU002 (see fig. 8) with Vancapticin 15 (see fig. 11). FU002 is significantly more active against VanA resistant Enterococcus faecium UL 602570
- FIG. 13 Direct comparison of Vancomycin-Vc-R3 with Vancomycin-Vc-R3 -Caproic acid.
- Vc- R3 is significantly more active against VanA resistant Enterococcus faecium UL 602570.
- Figure 14 Comparison of vancomycin with two different vancomycin conjugates containing either the peptide sequence of KKKKKKC (SEQ ID NO: 47) or RRRKKKC (SEQ ID NO: 48) on three different bacterial strains of Enterococci. No values for vancomycin-Vn- R3K3 on ATCC51299 and ATCC700327 are shown.
- Figure 15 Comparison of vancomycin with three different vancomycin conjugates consisting of a peptide with the sequence RRRRRRRRRC (SEQ ID NO: 16) coupled with a linker (SMCC) on the vancomycin- V fj -position (R9-conjugate), Vancapticin 14 (Blaskovich et al., Nature communications, 2018, 9:22; Table 1, Id 14) and Vancapticin 15 (see figure 11 and Blaskovich et al., Nature communications, 2018, 9:22; Table 1, Id 15).
- Figure 16 Deglycosylation of FU002 ensures the X 3 -position of the conjugated peptide. Analytic was performed by HPLC-MS.
- Figure 17 Effect on cell viability of the vancomycin conjugate FU002 (see figure 8) and vancomycin. Liver cells used were HepG2 cells and kidney cells are HEK-293 cells.
- Figure 18 Biodistribution studies of 125 I-radiolabeled FU002y and vancomycin in Wistar rats.
- Figure 19 Blood-level of 125 I-radiolabelled FU002y in comparison to vancomycin. No significant difference in the blood concentration between vancomycin and FU002 was detected.
- FIG. 20 PET-imaging of i.v. injected 124 I-radiolabelled FU002 shows after 10 minutes an accumulation in the liver in contrast to vancomycin, which is rapidly excreted by the kidneys. Insertion of longer PEG chains between vancomycin and the peptide moiety (PEG-FU002; PEG 24 chain) again dirigates to the kidneys.
- Figure 21 Minimal inhibitory concentrations of further vancomycin conjugates in direct comparison to vancomycin (Vanco) are depicted. The level of resistance of the particular strain is indicated in the graphs as dotted line.
- Figure 22 The structures of the vancomycin conjugates of figure 21 are depicted.
- A FU037
- B FU037
- FU040 (C) FU042, (D) FU043, (E) FU044 and (F) FU045.
- Figure 23 Overview of further vancomycin conjugates that have been synthesized. The MIC of these conjugates has been tested on E. faecium UL602570.
- Figure 24 Structure of the teicopianin conjugate FU003.
- Figure 25 MIC testing of FU003 (teicoplanin-conjugate) in comparison with teicopianin.
- FU003 shows improved (i.e. lower) MIC values and breaks the level of resistance.
- Figure 26 Structure of the daptomycin-conjugate FU004.
- Figure 29 An in vivo toxicity study in SWISS (CD-I) mice according to the standard dosing scheme of vancomycin was performed. Vancomycin and saline were used as controls.
- A Body weight development was not affected by treatment with the vancomycin conjugate FU002.
- B Four different blood parameters were assessed. Treatment with FU002 (upright triangle) did not adversely affect albumin levels (ALB), ala.niue- aminotransferase (ALT), alkaline phosphatase (ALP) or amylase (AMY). No toxic effects with respect to FU002 could be observed.
- ALB albumin levels
- ALT ala.niue- aminotransferase
- ALP alkaline phosphatase
- AMY amylase
- Figure 30 Vancomycin conjugate FU007, wherein the polypeptide is comprised in atachment ot position X4 (VR).
- the MIC value of FU007 for E.faecium UL602570 are 22,5625 pg/ml (i.e. 8.13978x1 O 09 mol/ml). Measurement of MIC values was performed twice in duplicate in a concentration of 3.61 mg/ml.
- the present invention relates to an antibiotic comprising at least one polypeptide P p of a length of 2 to 20 amino acids, preferably of a length of 2 to 12 amino acids, wherein the N-terminus of the polypeptide is not attached to a lipophilic group and the polypeptide preferably is positively charged and optionally a linker connecting the antibiotic and the polypeptide is comprised in the antibiotic.
- the present invention relates to an antibiotic of one of the structures (I) or (II)
- P p is a polypeptide of a length of 2 to 40, preferably 2 to 20, amino acids;
- L is a linker
- X j is selected from: -OH, -(NH) r -(CH 2 ) s -N-(CH 2 ) 2 , -P P and -L-P P ,
- r is selected from 0 or 1
- s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4,
- N-temiinus of P p is preferably not attached to a lipophilic group
- X 2 is selected from
- Y 9 is selected from -H, -(CH 2 ) V -NH 2 , -CCH 2 ) V -NH-(CH 2 ) W -CH 3 ,(4- halobiphenyl), -P p or -3 -P P , wherein v is an integer ranging from 1 to 4, w is an integer ranging from 6 to 12, P p is said polypeptide and L is said linker,
- Y 2 is selected from -H and -C3 ⁇ 4,
- Y 6 is selected from -H, and -0-Y 8 ,
- Y 8 is a substituted tetrahydrofiiranyl, preferably a substituted tetrahydrofuranyl- 3-4-diol, more preferably 2-(hydroxymethyl)tetrahydroftiranyl-3-3-diol, wherein Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C n alkyl; or
- a branched or unbranched C 3 to Ci 9 alkyl or alkenyl preferably a branched or unbranched C 5 to Cn alkyl or alkenyl, more preferably a C 5 to C l7 alkyl, most preferably a C 9 to C n alkyl.
- X 3 is selected from— NX 14 -CH 3 and -NH-X 15 ,
- X 14 is selected from -H, -P p and -L-P p ,
- X 15 is selected from -H, -P p and -L-P p ;
- X 4 is selected from -H, -(CH 2 ) n -NH -(03 ⁇ 4-R R -(CH 2 ) n -NH-(CH 2 ) tf -L-P P ; -(CH 2 ) n -NH-P P , - (CH 2 ) n -NH-L-P P -P p , -L-P p and a substituted phosphonic acid, preferably substituted methylamino-phosphonic acid, wherein n is an integer ranging from 1 to 4, preferably 2 to 3, wherein n’ is an integer ranging from 1 to 4, preferably 2 to 3;
- X 5 is selected from -H, and substituted tetrahydropyranyl, preferably amino-methyl-hydroxy- tetrahydropyranyl or (dihydroxy-hydroxymethyl-tetrahydropyran)-acetamide;
- Xe is selected from -H, -Cl, -F, -Br, and -I;
- X 7 is selected from -H, -Cl, -F, -Br, and -I;
- X 8 is selected from -H and -O-Y 10 ,
- Y 10 is selected from -H and substituted tetrahydropyranyl, preferably hydroxymethyl-trihydroxy-tetrahydropyranyl;
- X 9 is selected from -H or substituted tetrahydropyranyl, preferably hydroxymethyl— trihydroxy- tetrahydropyranyl or (methylacetate)-trihydroxytetrahydro-pyranyl;
- Xio is selected from acetamide and substituted or unsubstituted phenyl, preferably phenyl or halobenzyl, and
- Xu is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, preferably 2-methyl-proply, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl;
- Xio and Xu are linked by substituted or unsubstituted diphenyl ether, preferably a substituted or unsubstituted hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo- hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy-phenyl;
- X 12 is selected from -CH 2 -QH, -COOH, and -0-Y u ,
- Yu is substituted tetrahydropyranyl, preferably methyltrihydioxytetrahydropyranyl, wherein the antibiotic of (I) comprises at least one P P ;
- W is selected from -P p and -L-P p.
- the antibiotic of the first or second aspect is for use in the treatment or prophylaxis of a bacterial infection.
- the antibiotic of the first or second aspect is for use as a medicament.
- the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)” , Leuenberger, H.G.W, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
- alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaiyl, heteroaralkyl, alkenyl, heterocycloalkenyl and alkynyl are provided.
- alkyl refers to a saturated straight or branched carbon chain.
- the chain comprises from 1 to 10 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 e.g. methyl, ethyl methyl, ethyl, propyl. so-propyl, butyl, so-butyl, ferf-butyl, pentyl, hexyl, pentyl, or octyl.
- Alkyl groups are optionally substituted.
- heteroalkyl refers to a saturated straight or branched carbon chain.
- the chain comprises from 1 to 9 carbon atoms, i.e. 1, 2, 3, 4, , 6, 7, 8, 9 e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, .sec-butyl, ferf-butyl, pentyl, hexyl, pentyl, octyl, which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms.
- the heteroatoms are selected from O, S, and N, e.g.
- cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl etc.
- cycloalkyl and “heterocycloalkyl” are also meant to include bicyclic, tricyclic and polycyclic versions thereof.
- heterocycloalkyl preferably refers to a saturated ring having five of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N; a saturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a saturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms.
- “Cycloalkyl” and “heterocycloalkyl” groups are optionally substituted.
- a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
- cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1- cyclohexenyl, 3-cyclohexenyl, cycloheptyl, spiro[3,3]heptyl, spiro[3,4]octyl, spiro[4,3]octyl, spiro[3,5]nonyl, spiro[5,3]nonyl, spiro[3,6]decyl, spiro[6,3]decyl, spiro[4,5]decyl, spiro[5,4]decyl, bicyclo[2.2.
- heterocycloalkyl examples include 1 -(1 ,2,5 ,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, 1,8 diazo-spiro-[4,5] decyl, 1,7 diazo-spiro-[4,5] decyl, 1,6 diazo- spiro-[4,5] decyl, 2,8 diazo-spiro[4,5] decyl, 2,7 diazo-spiro[4,5] decyl, 2,6 diazo-spiro[4,5] decyl, 1,8 diazo-spiro-[5,4] decyl, 1,7 diazo-spiro-[5,4] decyl, 2,8 diazo-spiro-[5,4] decyl, 2,7 diazo-spiro-[5,4] decyl, 2,8 diazo-spiro-[5,4] decyl
- aryl preferably refers to an aromatic monocyclic ring containing 6 carbon atoms, an aromatic bicyclic ring system containing 10 carbon atoms or an aromatic tricyclic ring system containing 14 carbon atoms. Examples are phenyl, naphtyl or anthracenyl. The aryl group is optionally substituted.
- aralkyl refers to an alkyl moiety, which is substituted by aryl, wherein alkyl and aryl have the meaning as outlined above.
- An example is the benzyl radical.
- the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butenyl, teri-butyl, pentyl, hexyl, pentyl, octyl.
- the aralkyl group is optionally substituted at the alkyl and/or aryl part of the group.
- heteroaryl preferably refers to a five or six-membered aromatic monocyclic ring wherein at least one of the carbon atoms are replaced by 1, 2, 3, or 4 (for the five membered ring) or 1, 2, 3, 4, or 5 (for the six membered ring) of the same or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 8, 9, 10, 11 or 12 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 13, 14, 15, or 16 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S.
- Examples are oxazolyl, isoxazolyl, 1,2,5- oxadiazolyl, 1 ,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1 ,2,3 ,-thiadiazolyl, 1 ,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3- triazinyl, 1,2,4-triazinyl, 1,3,5-tiiazinyl, 1-benzofuranyl, 2-benzofuranyl, indoyl, isoindoyl, benzothiophenyl, 2-benzothiophenyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2, 1 -benzosoxazoyl, benzothiazo
- heteroarylkyl refers to an alkyl moiety, which is substituted by heteroaryl, wherein alkyl and heteroaryl have the meaning as outlined above.
- An example is the 2- alklypyridinyl, 3-alkylpyridinyl, or 2-methylpyridinyl.
- the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g.
- heteroaralkyl group is optionally substituted at the alkyl and/or heteroaryl part of the group.
- alkenyl and“cycloalkenyl” refer to olefinic unsaturated carbon atoms containing chains or rings with one or more double bonds. Examples are propenyl and cyclohexenyl.
- the alkenyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g.
- cycloalkenyl ring comprises from 3 to 8 carbon atoms, i.e. 3, 4, 5, 6, 7, or 8, e.g.
- heterocycloalkenyl preferably refers to olefinic unsaturated carbon atoms containing rings with one or more double bonds. At least one member of the ring is a N, O or S atom. A ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N.
- heterocycloalkenyl examples include azirine, diazirene, oxirene, thiirene, azete, diazete, oxete, dioxete, thiete, dithiete, pyrroline, furanyl, thiophenyl, imidazoline, pyrazoline, oxazoline, thiazoline, pyridine, pyran or thiopyran.
- alkynyl refers to unsaturated carbon atoms containing chains or rings with one or more triple bonds.
- An example is the propargyl radical.
- the alkynyl chain comprises from 2 to 8 carbon atoms, i.e.
- carbon atoms or hydrogen atoms in alkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl radicals may be substituted independently from each other with one or more elements selected from the group consisting of O, S, N or with groups containing one or more elements selected from the group consisting of O, S, N.
- Embodiments include alkoxy, cycloalkoxy, arykoxy, aralkoxy, alkenyloxy, cycloalkenyloxy, alkynyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, alkenylthio, cycloalkenylthio, alkynylthio, alkylamino, cycloalky lamino, arylamino, aralkylamino, alkenylamino, cycloalkenylamino, alkynylamino radicals.
- hydrogen atoms in alkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, alkenyl, cycloalkenyl, alkynyl radicals may be substituted independently from each other with one or more halogen atoms.
- One radical is the trifluoromethyl radical. If two or more radicals or two or more residues can be selected independently from each other, then the term“independently” means that the radicals or the residues may be the same or may be different.
- a wording defining the limits of a range of length such as, e. g.,“from 1 to 6” means any integer from 1 to 6, i. e. 1, 2, 3, 4, 5 and 6.
- any range defined by two integers explicitly mentioned is meant to comprise and disclose any integer defining said limits and any integer comprised in said range.
- halo refers to a halogen residue selected from the group consisting of F, Br, I and Cl.
- the halogen is Cl.
- linker and“L” are interchangeably used herein to refer to any chemically suitable linker.
- linkers are not or only slowly cleaved under physiological conditions.
- the linker does not comprise recognition sequences for proteases or recognition structures for other degrading enzymes.
- the compounds of the invention are administered systemically, it is preferred that the linker is chosen in such that it is not or only slowly cleaved in blood. The cleavage is considered slowly, if less than 50% of the linkers are cleaved 2 h after administration of the compound to a human patient.
- Suitable linkers comprises or consists of optionally substituted alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, aralkyl, heteroaralyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, sulfonyl, amines, ethers, thioethers phosphines, phosphoramidates, carboxamides, esters, imidoesters, amidines, thioesters, sulfonamides, 3 -thiopyrrolidine-2 , 5 -dion, carbamates, ureas, guanidines, thioureas, disulfides, oximes, hydrazines, hydrazides, hydrazones, diaza bonds, triazoles, triazolines, tetrazines, platinum complexes and
- amino acid refers to any organic acid containing one or more amino substituents, e.g. a-, b- or g-amino, derivatives of aliphatic carboxylic acids.
- amino substituents e.g. a-, b- or g-amino, derivatives of aliphatic carboxylic acids.
- polypeptide notation e.g. Xaa5, i.e. XaalXaa2Xaa3Xaa4Xaa5 , wherein Xaal to Xaa5 are each and independently selected from amino acids as defined, the left hand direction is the amino terminal direction and the right hand direction is the carboxy terminal direction, in accordance with standard usage and convention.
- conventional amino acid refers to the twenty naturally occurring amino acids, and encompasses all stereomeric isoforms, i.e. D, L-, D- and T ,-amino acids thereof.
- These conventional amino acids can herein also be referred to by their conventional three- letter or one- letter abbreviations and their abbreviations follow conventional usage (see, for example, Immunology— A Synthesis, 2nd Edition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates,
- non-conventional amino acid refers to unnatural amino acids or chemical amino acid analogues, e.g. a,a-disubstituted amino acids, N-alkyl amino acids, homo-amino acids, dehydroamino acids, aromatic amino acids (other than phenylalanine, tyrosine and tryptophan), and ortho-, meta- or para-aminobenzoic acid.
- Non-conventional amino acids also include compounds which have an amine and carboxyl functional group separated in a 1,3 or larger substitution pattern, such as b-alanine, g-amino butyric acid, Freidinger lactam, the bicyclic dipeptide (BTD) , amino-methyl benzoic acid and others well known in the art.
- BTD bicyclic dipeptide
- Statine-like isosteres, hydroxyethylene isosteres, reduced amide bond isosteres, thioamide isosteres, urea isosteres, carbamate isosteres, thioether isosteres, vinyl isosteres and other amide bond isosteres known to the art may also be used.
- analogues or non-conventional amino acids may improve the stability and biological half-life of the added peptide since they are more resistant to breakdown under physiological conditions.
- the person skilled in the art will be aware of similar types of substitution which may be made.
- a non-limiting list of non-conventional amino acids which may be used as suitable building blocks for a peptide and their standard abbreviations (in brackets) is as follows: a-aminobutyric acid (Abu), L-N-methylalanine (Nmala), a-amino-a- methylbutyrate (Mgabu), L-N-methylarginine (Nmarg), aminocyclopropane (Cpro), L-N- methylasparagine (Nmasn), carboxylate L-N-methylaspartic acid (Nmasp), aniinoisobutyric acid (Aib), L-N-methylcysteine (Nmcys), aminonorbomyl (Norb), L-N-methyl
- N-contaimng aromatic or non-aromatic mono or bicyclic heterocycle refers to a cyclic saturated or unsaturated hydrocarbon compound which contains at least one nitrogen atom as constituent of the cyclic chain.
- Suitable pharmaceutically acceptable salts of the compound of the present invention include acid addition salts which may, for example, be formed by mixing a solution of choline or derivative thereof with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate).
- alkali metal salts e.g., sodium or potassium salts
- alkaline earth metal salts e.g., calcium or magnesium salts
- suitable organic ligands e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sul
- Illustrative examples of pharmaceutically acceptable salts include but are not limited to: acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate
- compositions refers to a substance and/or a combination of substances being used for the identification, prevention or treatment of a tissue status or disease.
- the pharmaceutical composition is formulated to be suitable for administration to a patient in order to prevent and/or heat disease.
- a pharmaceutical composition refers to the combination of an active agent with a carrier, inert or active, making the composition suitable for therapeutic use.
- compositions can be formulated for oral, parenteral, topical, inhalative, rectal, sublingual, transdermal, subcutaneous or vaginal application routes according to their chemical and physical properties.
- Pharmaceutical compositions comprise solid, semisolid, liquid, transdermal therapeutic systems (TTS).
- Solid compositions are selected from the group consisting of tablets, coated tablets, powder, granulate, pellets, capsules, effervescent tablets or transdermal therapeutic systems.
- liquid compositions selected from the group consisting of solutions, syrups, infusions, extracts, solutions for intravenous application, solutions for infusion or solutions of the carrier systems of the present invention.
- Semisolid compositions that can be used in the context of the invention comprise emulsion, suspension, creams, lotions, gels, globules, buccal tablets and suppositories.
- “Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered.
- Such pharmaceutical carriers can be sterile liquids, such as saline solutions in water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- a saline solution is a preferred carrier when the pharmaceutical composition is administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatine, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E. W. Martin.
- the present invention relates to a, antibiotic comprising at least one polypeptide of a length of 2 to 20 amino acids, preferably of a length of 2 to 12, more preferably 3 to 10 amino acids, even more preferably 4 to 8 amino acids and most preferably 6 amino acids, wherein the N-terminus of the polypeptide is not attached to a lipophilic group and is preferably positively charged and optionally comprises a linker connecting the antibiotic and the polypeptide.
- lipophilic group is used herein in its meaning known in the art of chemistry. Lipophilic refers to the ability of a chemical compound to dissolve in fats, oils, lipids and non polar solvents. This definition includes e.g. lipophilic membrane insertive elements. Preferred examples include saturated and unsaturated fatty acids, C8 to C22 fatty acids, cholesterol, derivatives of cholesterol, phospholipids, glycolipids, glycerol esters, steroids, ceramids, isoprene derivatives, adamantane, famesol, aliphatic groups, or polyaromatic compounds. Preferred lipohilic groups that may be attached to the P P in some embodiments are myristoyl (C 14), palmitoyl (C 16) or stearoyl (C 18), more preferably myristoyl (C 14).
- the present invention relates to an antibiotic comprising an antibiotic core and at least one polypeptide of a length of 2 to 20 amino acids, preferably of a length of 2 to 12 amino acids, wherein the N-terminus of the polypeptide is not attached to a lipophilic group and the polypeptide is positively charged and optionally a linker connecting the antibiotic core and the polypeptide, wherein the antibiotic core is selected from the group consisting of a glycopeptide antibiotic; a cyclic lipopeptide antibiotic; a b-lactam antibiotic, a cephalosporine antibiotic; and an oxazolidinone antibiotic; preferably a glycopeptide antibiotic and a cyclic lipopeptide antibiotic.
- the lipophilic group is not attached to any other position of the polypeptide including, but not limited to, the C- terminus and side chains of the polypeptide.
- the antibiotic core is selected from the group consisting of a glycopeptide antibiotic; a cyclic lipopeptide antibiotic; a B-lactam antibiotic, preferably a cephalosporine antibiotic; an oxazolidinone antibiotic; and an aminoglycoside antibiotic.
- the antibiotic core is selected from the group consisting of a glycopeptide antibiotic; a cyclic lipopeptide antibiotic; a B-lactam antibiotic, a cephalosporine antibiotic; and an oxazolidinone antibiotic.
- the antibiotic core is selected from a glycopeptide antibiotic or a cyclic lipopeptide antibiotic.
- glycopeptide antibiotic is selected from the group consisting of vancomycin, teicoplanin, A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850, A84575, AB-65, actaplanin, actinoidin, ardacin, avoparcin, azureomycin, balhimycin, chloroorientiein, chloropolyspoiin, dalbavancin, decaplanin, N-demethylvancomycin, eremomycin, galacardin, helvecardin, izupeptin, kibdelin, LL-AM374, mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, orenticin, parvodicin, ristor
- cyclic lipopeptide antibiotic is selected from the group consisting of daptomycin, dalbavancin, oritavancin and telavancin ;
- aminoglycoside antibiotic is selected from the group consisting of amikacin, and kanamycin;
- B-lactam antibiotic is selected from the group consisting of penicillin, amoxicillin, and ampicillin;
- cephalosprine antibiotic is selected from the group consisting of cefazolin, cefadroxil, cephalexin, cefiiroxim, cefotiam, cefaclor, cefiiroxim, loracarbef, cefixim, cefpodoxim, ceftibuten, cefotaxim, ceftriaxon, ceftazidim, cefepim ceftobiprol, ceftolozan, or ceftarolin, and
- glycopeptide antibiotic is selected from the group consisting of vancomycin, teicoplanin, A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850, A84575, AB-65, actaplanin, actinoidin, ardacin, avoparcin, azureomycin, balhimycin, chloroorientiein, chloropolysporin, dalbavancin, decaplanin, N-demethylvancomycin, eremomycin, galacardin, helvecardin, izupeptin, kibdelin.
- cyclic lipopeptide antibiotic is selected from the group consisting of daptomycin, dalbavancin, oritavancin and telavancin ;
- b-lactam antibiotic is selected from the group consisting of penicillin, amoxicillin, and ampicillin;
- cephalosprine antibiotic is selected from the group consisting of cefazolin, cefadroxil, cephalexin, cefuroxim, cefotiam, cefaclor, cefuroxim, loracarbef, ceftxim, cefpodoxim, ceftibuten, cefotaxim, ceftriaxon, ceftazidim, cefepim ceftobiprol, ceftolozan, or ceftarolin, and
- Glycopeptide antibiotics are most preferred and in particular vancomycin and structural derivatives thereof, in particular teicoplanin, avoparcin, ristocetin, parvodicin, oritavancin, dalbavancin and telavancin.
- the polypeptide or the linker forms a bond to the indicated residues of structures (I) and (II) as defined in the second aspect of the invention.
- the present invention relates to an antibiotic of one of the structures (I) or
- P p is a polypeptide of a length of 2 to 40, preferably 2 to 20, amino acids, more preferably 3 to 10 amino acids;
- L is a linker
- X j is selected from: -OH, -(NH) r -(CH 2 ) s -N-(CH 2 ) 2 , -P P and -L-P P ,
- r is selected from 0 or 1
- s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4,
- N-terminus of P p is preferably not attached to a lipophilic group
- X 2 is selected from structure (
- Yi is selected from -H, -OH, and -NH-Y 9 ,
- Y 9 is selected from -H, -(CH 2 ) V -NH 2 , -(CH 2 ) V -NH-(CH 2 ) W -CH 3 , -(CH 2 ) q - chlorobiphenyl chlorobiphenyl, -P p and -L-P p , wherein q is an integer ranging from 1 to 4, preferably 1 to 2, v is an integer ranging from 1 to 4, w is an integer ranging from 6 to 12, P p is said polypeptide and L is said linker,
- Y 2 is selected from -H and -C3 ⁇ 4,
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C n alkyl; or
- a branched or unbranched C 3 to C 19 alkyl or alkenyl preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C n alkyl.
- X 3 is selected from -NX 14 -CH 3 and -NH-X 15 ,
- X l4 is selected from -H, -P P and -L-P P ,
- C 5 is selected from -H, -P P and -L-P P ;
- X is selected from -H, -(CH 2 ) n -NH -(CH 2 ) n -P P, -(CH 2 ) n -NH-(CH 2 ) n -L-P P ; -(CH 2 ) n -NH-P P , -
- 3 ⁇ 4 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 7 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- Xs is selected from -H and -O-Y l0 ,
- X l0 is selected from acetamide and substituted or unsubstituted phenyl, preferably substituted with one or two halogens, in particular phenyl or halobenzyl,
- Xu is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, most preferably 2-methyl-propyl, substituted phenyl, preferably methyl-frihydroxy-tetrahydropyranyl substituted phenyl; or
- X 10 and X u are linked by a substituted or unsubstituted diphenyl ether, preferably each phenyl ring independently substituted with one or two substituents selected from -OH, and halogen, in particular hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, fraio- hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy-phenyl;
- X 12 is selected from -CH 2 -OH, -COOH, and -0-Y U ,
- the antibiotic of (I) comprises at least one P p , more preferably 1 or 2 P p most preferably one P p ;
- Wi is selected from -P p and -L-P p.
- the present invention relates to an antibiotic of one of the structures (I) or (II)
- P p is a polypeptide of a length of 2 to 40, preferably of 2 to 20, amino acids;
- L is a linker
- X j is selected from: -OH, -(NH) r -(CH 2 ) s -N-(CH 2 ) 2 , -(NH)-(CH 2 ) U -(NH)-P p , -(NH)-(CH 2 ) U -
- u is an integer ranging from 1 to 4, preferably 2 to 3, r is selected from 0 or 1, s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4, t is an integer ranging from 2 to 18, preferably 4 to 16,
- X 2 is selected from structure (
- Y t is selected from -H, -OH, and -NH-Y 9 ,
- Y 2 is selected from -H and -C3 ⁇ 4,
- Y 6 is selected from -H, and -0-Y 8 ,
- Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofiiranyl-3-4-diol, more preferably 2-(hydroxymethyl)tetrahydrofuranyl-3-3- diol,
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9
- a branched or unbranched C 3 to C 19 alkyl or alkenyl preferably a branched or unbranched C 5 to C l7 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to Cn alkyl.
- X 3 is selected from -NX l4 -CH 3 and -NH-X 15 ,
- X is selected from -H, -(CH 2 ) n - H -(CH ⁇ -Pp, -(CH 2 ) n -NH-(CH 2 ) ⁇ -L-P P ; -(CH 2 ) n -NH- P P , -(CH 2 ) n -NH-L-P P -Pp, -L-P P and a substituted phosphonic acid, preferably substituted methylamino-phosphonic acid, wherein n is an integer ranging from 1 to 4, preferably 2 to 3, wherein n’ is an integer ranging from 1 to 4, preferably 2 to 3;
- X 5 is selected from -H, or substituted tetrahydropyranyl, preferably amino-methyl- hydroxy-tetrahydropyranyl or (dihydroxy-hydroxymethyl-tetrahydropyran)-acetamide ;
- Xg is selected fr om -H, -Cl, -F, -Br, and -I;
- X 7 is selected from -H, -Cl, -F, -Br, and -I;
- X g is selected from -H and -O-Y 10 ,
- Y 10 is selected from -H or substituted tetrahydropyranyl, preferably hydroxymethyl-trihydroxy-tetrahydropyranyl;
- X 9 is selected from -H and substituted tetrahydropyranyl, preferably hydroxymethyl— frihydiOxy-tetrahydropyranyi or (methylacetate)-trihydroxytetrahydro-pyranyl;
- X 10 is selected from acetamide and substituted or unsubstituted phenyl, preferably phenyl or halobenzyl, and
- X n is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or
- X 10 and X n are linked by a unsubstituted or substituted diphenyl ether, preferably a substituted or unsubstituted hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo-hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy- phenyl;
- X 12 is selected from -C3 ⁇ 4-OH, -COOH, -0-Y U ,
- Y n is substituted tetrahydropyranyl, preferably methyltiihydioxytefrahydiopyranyl,
- antibiotic of (I) comprises at least one P P ;
- Structure (I) represents the backbone of at least the following glycopeptides and lipoglycopeptides: vancomycin, teicoplanin, avoparcin, ristocetin, parvodicin, oritavancin, dalbavancin and telavancin.
- Elements Xi to X 4 comprise the atachment points of P P or the linker to which the P P is bound, if present, to the antibiotic according to structure (I).
- the antibiotic according to structure (I) comprises one or two, preferably one P p or L-P p. Accordingly, in the following preferred embodiments are indicated in which P p or L-P p are attached to either X t , X 2 , X 3 or X 4
- Element X t is part of a carboxyl group located at this position in the unmodified antibiotics. However, this position can not only be modified by the P p , but also by other structures as indicated herein to increase the antimicrobial activity of the antibiotic.
- X x is selected from -P p or -L-P p ;
- X x is selected from -(NH)-(CH 2 ) U -(NH)-P p , -(NH)- (CH 2 ) U -(NH)-L-Pp, wherein u is an integer ranging from 1 to 4, preferably 2 to 3.
- Xi is selected from -(NH)-(CH 2 ) U -(NH)-L-P P , wherein u is an integer ranging from 1 to 4, preferably 2 to 3.
- X 2 is selected from structure (PI), and -NH-CO-Y 3 ,
- Yi is selected from -H, -OH, and -NH-Y 9 ,
- Y 6 is selected from -H, and -0-Y 8 ,
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl, i.e. C 8 , C 9 , C l0 , C u or C 12 alkyl; or C 8 to C l2 alkenyl, , i.e.
- C 8 , C 9 , C 10 , C n or C 12 alkenyl preferably a C 9 alkyl, C 9 alkenyl or a C n alkyl; non-3-en-yl (as in Teicoplanin A 2 -l), 7-methyl-octanyl (as in Teicoplanin A -2), nonyl (as in Teicoplanin A 2 -3), 7-methyl-nonyl (as in Teicoplanin A 2 -4), or 8-methyl-nonyl
- X 3 is selected from -NX 14 -CH 3 and -NH-X 15 ,
- X4 is selected from -H, and a substituted phosphonic acid, preferably substituted methylamino- phosphonic acid;
- Xe is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 7 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 8 is selected from -H and -O-Y 10 ,
- X 10 is selected from acetamide and substituted or unsubstituted phenyl, preferably substituted with one or two halogens, in particular phenyl or halobenzyl,
- X 3l is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, most preferably 2-methyl-propyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or
- X10 and Xu are linked by a substituted or unsubstituted diphenyl ether, preferably each phenyl ring independently substituted with one or two substituents selected from -OH, and halogen, in particular hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo- hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy-phenyl;
- X 12 is selected from -CH 2 -OH, -COOH, and -0-Y u ,
- X 2 is selected from structure (III), and -NH-CO-Y 3.
- the variable Y 1 is selected from -H, -OH, -NH-Y9, wherein Y 9 is selected from -(CH 2 ) V -NH 2 , - (CH 2 VNH-(CH 2 ) W -CH 3 , -(CH 2 ) q -chlorobiphenyl and chlorobiphenyl.
- the index v is an integer ranging from 1 to 4
- q is an integer ranging from 1 to 4
- the index w is an integer ranging from 6 to 12.
- variable Y 2 is -H or -CH 3
- variable Y 6 is selected from -H, -0-Y 8 , wherein Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl- 3-4-diol, more preferably 2-(hydroxymethyl)tetrahydrofuranyl-3-3-diol.
- variable Y 3 is (i) a branched or unbranched C 8 to C i2 alkyl or alkenyl, preferably a C 9 alkenyl or a C n alkyl; or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C j 7 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C n alkyl.
- X 2 is selected from structure (III) and the variable Y j is selected from NH-Y 9 , wherein Y 9 is selected from H and variable Y 2 is CH 3.
- X 2 is -NH-CO-Y 3.
- the variable Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl, more preferably non-3-en-yl (as in Teicoplanin A 2 -l), 7 -methyl-octanyl (as in Teicoplanin A 2 -2), nonyl (as in Teicoplanin A 2 -3), 7-methyl-nonyl (as in Teicoplanin A 2 -4), or 8-methyl-nonyl (as in
- Teicoplanin A 2 -5 Teicoplanin A 2 -5); or (ii) a branched or unbranched C 3 to C l9 alkyl or alkenyl, preferably a branched or unbranched C 5 to C l7 alkyl or alkenyl, more preferably a C 5 to C l7 alkyl, most preferably a C 9 to C n alkyl.
- X 2 is structure (III).
- the variable Y j is selected from -H, -OH, and -NH-Y 9 , wherein Y 9 is selected from -(CH 2 ) V -NH 2 , -(CH 2 ) ⁇ -NH-(CH 2 ) W -CH 3 , -(CH 2 ) q - chlorobiphenyl and chlorobiphenyl.
- the index v is an integer ranging from 1 to 4
- q is an integer ranging from 1 to 4
- the index w is an integer ranging from 6 to 12.
- variable Y 2 is -H or -CH 3
- variable Y 6 is selected from -H, -0-Y 8 , wherein Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl-3 -4-diol, more preferably 2- (hydroxymethyl)tetrahydrofuranyl-3-3-diol.
- variable Yi of structure (III) is selected from -H, -OH,
- the variable Y 2 of structure (ITT) is -H or -CH 3.
- the variable Y 3 of the structure of element X 2 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl; or (ii) a branched or unbranched C 3 to C j9 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C u alkyl.
- the variable Y 6 of structure (ITT) is
- variable Uc of structure (ITT) is selected from -H, -OH,
- variable Y of the structure of element X 2 is -H or -C3 ⁇ 4.
- variable Y 3 of element X 2 is (i) a branched or unbranched C 8 to Ci 2 alkyl or alkenyl, preferably a C 9 alkenyl or a Cn alkyl; or (ii) a branched or unbranched C 3 to C l9 alkyl or alkenyl, preferably a branched or unbranched C 5 to Ci 7 alkyl or alkenyl, more preferably a C 5 to C l7 alkyl, most preferably a C 9 to C u alkyl.
- variable Y 6 of structure (TIT) is selected from -H or
- X4 is selected from -H, and a substituted phosphonic acid, preferably substituted methylamino phosphonic acid.
- P P is linked through its N-terminus to the carbonyl group forming a peptide bond. If -L-P P is attached at position XI P P may be linked through its N- or C-terminus to L.
- P p is attached at position X j it is preferred that it is present under the proviso that the N- terminus of P p is not attached to a lipophilic group.
- P p comprises Arg, in particular comprises or consists of 3 to 9 consecutive Arg than a lipophilic group may be attached to the N-terminus.
- the lipophilic group is not attached to any other position of the polypeptide including, but not limited to, the C-terminus and side chains of the polypeptide.
- Element X 2 is located on the mannose derived structure indicated in structure (I).
- X 2 has structure (PI)
- Y c is -NH-Yg, wherein Y 9 is selected from -(CH 2 ) U - ⁇ NH)-P p , -(CH 2 ) deliberately-(NH)-L-P p , -P p and -L-Pp.
- u is an integer ranging from 1 to 4, preferably 2 to 3.
- variable Y 2 is -H or -C3 ⁇ 4
- variable Y 6 is selected from -H, and -0-Y 8 , wherein Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl-3-4-diol, more preferably 2- (hydroxymethyl)tetrahydrofuranyl-3-3-diol.
- r is selected from 0 or 1
- s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4
- t is an integer ranging from 2 to 18, preferably 4 to 16;
- X 3 is selected from -NX 14 -CH 3 and -NH-X l5 ,
- X 4 is selected from -H, and a substituted phosphonic acid, preferably substituted methylamino- phosphonic acid;
- Xg is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 7 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X s is selected from -H and -O-Y l0 ,
- X l0 is selected from acetamide and substituted or unsubstituted phenyl, preferably substituted with one or two halogens, in particular phenyl or halobenzyl,
- Xu is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, most preferably 2-methyl-propyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or X 10 and X u are linked by a substituted or unsubstituted diphenyl ether, preferably each phenyl ring independently substituted with one or two substituents selected from -OH, and halogen, in particular hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, fraio- hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy-phenyl;
- X l2 is selected from -CH 2 -OH, -COOH, and -0-Y u ,
- X j is selected from - OH, and -(NH) r -(CH 2 ) s -N-(CH 2 ) 2.
- the index r is selected from 0 or 1 , with 0 signifying the absence of the indicated element.
- Index s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4, most preferably 4.
- the modification -(CH 2 ) 4 -N-(CH 2 ) 2 refers to a modification disclosed in Yarlagadda et al. (J Med Chem. 2014 Jun 12;57(11):4558-68).
- X 4 is selected from -H, and a substituted phosphonic acid, preferably substituted methylamino phosphonic acid.
- the N-terminus of the polypeptide P p comprised in element X 2 is not attached to a lipophilic group.
- the lipophilic group is not attached to any other position of the polypeptide P p comprised in element X 2 including, but not limited to, the C -terminus and side chains of the polypeptide.
- Element X 3 is located at the position of a methyl amine group in the unmodified antibiotic.
- one of X l4 and X l5 is selected from -(CH 2 ) U -(NH)-P p , -(CH 2 ) n -(NH)-L-Pp, -P P or -L-P P and the other is -H, wherein u is an integer ranging from 1 to 4, preferably 2 to 3;
- r is selected from 0 or 1
- s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4
- t is an integer ranging from 2 to 18, preferably 4 to 16;
- X 2 is selected from structure (PI), and -NH-CO-Y 3 ,
- Y x is selected from-H, -OH, and -NH-Y 9 ,
- Y 2 is selected from -H and -C3 ⁇ 4, wherein Y 6 is selected from -H, and -0-Y 8 ,
- Y 3 is (i) a branched or unbranched C 8 to C l2 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl; or
- a branched or unbranched C 3 to C 19 alkyl or alkenyl preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C n alkyl.
- X 4 is selected from -H, and a substituted phosphonic acid, preferably substituted methylamino- phosphonic acid;
- Xg is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 7 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 8 is selected from -H and -O-Y 10 ,
- X 10 is selected from acetamide and substituted or unsubstituted phenyl, preferably substituted with one or two halogens, in particular phenyl or halobenzyl,
- X u is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, most preferably 2-methyl-propyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or
- Xio and X u are hnked by a substituted or unsubstituted diphenyl ether, preferably each phenyl ring independently substituted with one or two substituents selected from -OH, and halogen, in particular hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo- hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy-phenyl;
- X 12 is selected from -CH 2 -OH, -COOH, and -0-Y u ,
- X t is selected from -OH, and -(NH) r -(CH 2 ) s -N-(CH 2 )2 ⁇
- the index r is selected from 0 or 1, with 0 signifying the absence of the indicated element.
- Index s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4, most preferably 4.
- X is selected from structure (III), and -NH-CO-Y 3.
- the index q is an integer ranging from 1 to 4, preferably 1 to 2, v is an integer ranging from 1 to 4, t is an integer ranging from 4 to 16 and the index w is an integer ranging from 6 to 12'.
- the variable Y 2 is -H or -CH 3
- the variable Y 6 is selected from -H, -0-Y 8 , wherein Y 8 is a
- variable Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl; or (ii) a branched or unbranched C 3 to C l9 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C u alkyl.
- X 2 is selected from structure (III) and the variable Y j is selected from NH-Y 9 , wherein Y 9 is selected from H and variable Y 2 is CH 3.
- X 2 is -NH-CO-Y 3.
- the variable Y 3 is (i) a branched or unbranched C 8 to C l2 alkyl or alkenyl, preferably a C 9 alkenyl or a Cu alkyl, more preferably non-3-en-yl (as in Teicoplanin A 2 -l), 7 -methyl-octanyl (as in Teicoplanin A 2 -2), nonyl (as in Teicoplanin A 2 -3), 7-methyl-nonyl (as in Teicoplanin A 2 -4), or 8-methyl-nonyl (as in
- Teicoplanin A 2 -5 Teicoplanin A 2 -5); or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C n alkyl.
- X 2 is structure (PI).
- the variable Y j is selected from -H, -OH, and -NH-Y 9 , wherein Y 9 is selected from -(CH 2 ) V -NH 2 , -(CH 2 ) ⁇ -NH-(CH 2 ) W -CH 3 , -(CH 2 ) q - chlorobiphenyl and chlorobiphenyl.
- the index v is an integer ranging from 1 to 4
- q is an integer ranging from 1 to 4
- the index w is an integer ranging from 6 to 12.
- variable Y 2 is -H or -C3 ⁇ 4
- the variable Y 6 is selected from -H, -0-Y 8 , wherein Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl-3 -4-diol, more preferably 2- (hydroxymethyl)tetrahydrofiiranyl-3-3-diol.
- the variable Y 3 of structure (ITT) is selected from -H, -OH,
- variable Y 2 of structure (ITT) is -H or -CH 3 .
- the variable Y 3 of the structure of element X 2 is (i) a branched or imbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl; or (ii) a branched or unbranched C 3 to
- C j9 alkyl or alkenyl preferably a branched or imbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C u alkyl.
- the variable Y 6 of structure (PI) is
- variable Y 3 of structure (III) is selected from -H, -OH,
- variable Y 2 of the structure of element X 2 is -H or -CH .
- variable Y 3 of element X 2 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a Cu alkyl; or (ii) a branched or imbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C l7 alkyl, most preferably a C 9 to Cu alkyl.
- variable Y 6 of structure (III) is selected from -H or
- X 4 is selected from -H, and a substituted phosphonic acid, preferably substituted methylamino phosphonic acid. In a more preferred embodiment, X 4 is selected from
- Pp may be attached through its N- or C -terminus.
- the N-terminus of the polypeptide P p comprised in element X 3 is not attached to a lipophilic group.
- the lipophilic group is not attached to any other position of the polypeptide P P comprised in element X 3 including, but not limited to, the C -terminus and side chains of the polypeptide.
- Element X 4 is located on an aromatic ring structure of the antibiotic.
- X 4 is selected from - (CH 2 ) n -NH -(CH 2 ) tf -P P -(C3 ⁇ 4) I1 -NH-(CH 2 ) n , -L-P P ; -(C3 ⁇ 4) n -NH-P P , -(CH 2 ) n -NH-L-P P -P p , and - L-P p , wherein n is an integer ranging from 1 to 4, preferably 2 to 3, wherein n is an integer ranging from 1 to 4, preferably 2 to 3, optionally n and/or n’ can be 0.
- r is selected from 0 or 1
- s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4
- t is an integer ranging from 2 to 18, preferably 4 to 16;
- X 2 is selected from structure (III), and -NH-CO-Y 3 ,
- Yi is selected from -H, -OH, and -NH-Y 9 ,
- Y 2 is selected from -H and -CH 3 ,
- Y 6 is selected from -H, and -0-Y 8 ,
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl; or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to Cn alkyl;
- X 3 is selected from -NX I4 -CH 3 and -NH-Xu,
- 3 ⁇ 4 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X 7 is selected from -H, -Cl, -F, -Br, and -I, preferably H and Cl;
- X s is selected from -H and -O-Y 10 ,
- Xio is selected from acetamide and substituted or unsubstituted phenyl, preferably substituted with one or two halogens, in particular phenyl or halobenzyl,
- X n is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, most preferably 2-methyl-propyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or
- X 10 and Xu are linked by a substituted or unsubstituted diphenyl ether, preferably each phenyl ring independently substituted with one or two substituents selected from -OH, and halogen, in particular hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, haio- hydroxyphenoxy-plienyl or methyl-hydroxyphenoxy-phenyl;
- X 12 is selected from -C3 ⁇ 4-OH, -COOH, and -0-Y u ,
- X t is selected from -OH, and -(NH) r -(CH 2 ) s -N-(CH 2 )2.
- the index r is selected from 0 or 1, with 0 signifying the absence of the indicated element.
- Index s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4, most preferably 4.
- X 2 is selected from structure (III), and -NH-CO-Y3.
- the variable Y 1 is selected from -H, -OH, -NH-Y 3 ⁇ 4 wherein Y 9 is selected from -(CH 2 ) V -NH 2 , -(CH 2 ) V - NH-(CH 2 ) W -CH 3 , -(CH 2 ) q -chlorobiphenyl and chlorobiphenyl.
- the index q is an integer ranging from 1 to 4, preferably 1 to 2
- v is an integer ranging from 1 to 4
- the index w is an integer ranging from 6 to 12'.
- variable Y 2 is -H or -C3 ⁇ 4
- variable Y 6 is selected from -H, -0-Y 8 , wherein Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl-3-4-diol, more preferably 2-(hydroxymethyl)tetrahydrofuranyl-3 -3 -diol.
- variable Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl; or (ii) a branched or unbranched C 3 to C19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C17 alkyl or alkenyl, more preferably a C 5 to C17 alkyl, most preferably a C 9 to C alkyl.
- X 2 is selected from structure (III) and the variable Y 1 is selected from NH-Y 9 , wherein Y 9 is selected from H and variable Y 2 is CH 3 .
- X 2 is -NH-CO-Y 3 .
- the variable Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C u alkyl, more preferably 11011- 3-en-yl (as in Teicoplanin A 2 -l), 7-methyl-octanyl (as in Teicoplanin A 2 -2), nonyl (as in Teicoplanin A 2 -3), 7-methyl-nonyl (as in Teicoplanin A 2 -4), or 8-methyl-nonyl (as in Teicoplanin A -5); or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or imbranched C 5 to C l7 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to Cu al
- X 2 is structure (PI).
- the variable Y 1 is selected from -H, -OH, and -NH-Y 9 , wherein Y 9 is selected from -(CH 2 ) V -NH 2 , -(CH 2 ) ⁇ -NH-(CH 2 ) W -CH 3 , -(CH 2 ) q - chlorobiphenyl and chlorobiphenyl.
- the index q is an integer ranging from 1 to 4, preferably 1 to 2
- v is an integer ranging from 1 to 4
- the index w is an integer ranging from 6 to 12.
- variable Y 2 is -H or -CH 3
- variable Y 6 is selected from -H, -0-Y 8 , wherein Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl-3 -4-diol, more preferably 2- (hydroxymethyl)tetrahydrofuranyl-3-3-diol.
- variable Y 1 of structure (III) is selected from -H, -OH, 2 (III) is -H or -CH 3.
- the variable Y 3 of the structure of element X 2 is (i) a branched or unbranched C 8 to Ci 2 alkyl or alkenyl, preferably a C 9 alkenyl or a C n alkyl; or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to Cn alkyl.
- the variable Y 6 of structure (III) is selected from -H and
- variable Uc of structure (III) is selected from -H, -OH,
- variable Y 2 of the structure of element X 2 is -H or -C3 ⁇ 4.
- variable Y 3 of element X 2 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a Cn alkyl; or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to C n alkyl.
- variable Y 6 of structure (III) is selected from -H and
- P p may be attached through its N- or C -terminus.
- the N-terminus of the polypeptide P p comprised in element X 4 is not attached to a lipophilic group.
- the lipophilic group is not attached to any other position of the polypeptide P p comprised in element X4 including, but not limited to, the C -terminus and side chains of the polypeptide.
- the elements X 5 to X 12 provide modifications to the backbone structure of the antibiotic according to structure (I) have the below preferred and particularly preferred meanings.
- X l3 X 2 , X 3 or X 4 is or comprises -P p or -L-Pp X 5 to j 2 have the following preferred meanings.
- X 5 is selected from -H, or substituted tetrahydropyranyl, preferably amino-methyl-hydroxy-tetrahydropyranyl or (dihydroxy-hydroxymethyl- tetrahydropyran)-acetamide.
- X 5 is selected from
- X 6 is selected from -H or a halogen, preferably -Cl.
- X 7 is selected from -H or a halogen, preferably -Cl.
- X 8 is selected from -H or -O-Y 10.
- the variable Y 10 is selected from -H or a substituted tetrahydropyranyl, preferably hydroxymethyl— trihydroxy- tetrahydropyranyl .
- X 8 is selected from -OH, -H, and
- X 9 is selected from -H or a substituted tetrahydropyranyl, preferably hydroxymethyl— trihydroxy-tetrahydropyranyl or (methylacetate)- trihydroxytetrahydro-pyranyl.
- X 9 is selected from -H and
- Y 7 is selected from -H or -CO-CH 3.
- X 10 is selected from a acetamide or substituted or unsubstituted phenyl, preferably phenyl or halobenzyl.
- X 10 is selected from and
- Y 5 is selected from -H or -Cl.
- X n is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl. In a more preferred embodiment, X n is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl,
- the elements X 10 and Xu are linked by an element.
- X l0 and u are linked by substituted phenyl ether, preferably a substituted or unsubstituted hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo-hydroxyphenoxy- phenyl or methyl-hydroxyphenoxy-phenyl.
- X 10 and X u are linked by
- Y 4 is selected from -H, -CH , or -Cl.
- X 12 is selected from -CH 2 -OH, -COOH, -0-Y n
- Yu is substituted tetrahydropyranyl, preferably methyltrihydroxytetrahydropyranyl.
- X 12 is selected from -CH 2 -OH, -COOH or
- the substituents g to X 12 take on their respective meaning in vancomycin and structural derivatives thereof, in particular teicoplanin, avoparcin, ristocetin, parvodicin, oritavancin, dalbavancin and telavancin, wherein one or two, preferably one of X l or X 4 is or comprises -P p or -L-P p or X 2 or X 3 comprises -P p or -L-P p.
- X l or X 4 is or comprises -P p or -L-P p or one of X 2 or X 3 comprises -P p or -L-P p
- X j is OH
- X 2 is structure (PI) and Yi is -NH 2
- Y 2 is CH 3 and Y 6 is -H
- X 3 is -NH-CH 3
- X 4 to X 7 is H
- X 8 is -OH
- X 9 is -H
- Xu is-2-mehtyl-propyl
- C 2 is -CH 2 -OH.
- one of Xu or X 4 is or comprises-P P or -L-P p or one of X 2 or X 3 comprises -P p or -L-P p
- X x is -OH
- X 2 is -NH-CO-Y3
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C n alkyl, more preferably non-3-en-yl (T eicoplanin A 2 - 1 ) , 7-methyl-octanyl (Teicoplanin A 2 - 2), nonyl (Teicoplanin A 2 -3), 7-methyl-nonyl (Teicoplanin A 2 -4), 8-methyl-nonyl (Teicoplanin A 2 -5); or (ii)
- element W 1 is selected from -P p or— L-P p.
- P p is the polypeptide according to the present invention and L is said linker.
- the N-terminus of the polypeptide P p comprised in element W 1 is not attached to a lipophilic group.
- the lipophilic group is not attached to any other position of the polypeptide P p comprised in element W x including, but not limited to, the C-terminus and side chains of the polypeptide.
- element Wf is selected from— L-P P.
- P P is the polypeptide according to the present invention and L is said linker.
- the inventors surprisingly found that the polypeptide of the present invention enables the antibiotic structure modified by the polypeptide to overcome a mechanism of resistance towards the unmodified antibiotic.
- the Antibiotic-polypeptide conjugates are not prone to common mechanisms of resistance against antibiotics such as vancomycin.
- the conjugates are antimicrobial active against bacteria with antibiotic resistances such as VanA, VanB and VanC types of resistance. Even against intrinsic vancomycin resistant bacteria like Lactobacillus pentosus, the antibiotic conjugates are sensitive. This suggests that the conjugates have an additional mode of action, compared to the unmodified antibiotic. Compared to vancomycin the results of MBC-testing of conjugates revealed a faster bactericidal mechanism of action (figure 9).
- the polypeptide comprises 2 to 30, preferably 2 to 15, more preferably 2 to 10, most preferably 3 to 10, positively charged amino acid residues.
- a positively charged amino acid has at a physiologic pH (pH 5-8) a positively charged side chain.
- positively charged proteinogenic amino acids include arginine, lysine and histidine.
- Non-proteinogenic amino acids can also be used in the present invention as long as the amino acids are positively charged.
- suitable non-proteinogenic amino acids are a-aminoglycine, ornithine, 4,5-dehydrolysine, homoarginine, 4-aminophenylalanine and 3 -aminotyrosine.
- the polypeptide comprises 2 to 30, preferably 2 to 15, more preferably 2 to 10, most preferably 3 to 10, lysine and/or arginine residues.
- the polypeptide is linear or circular, preferably linear, and:
- (i) has a length of between 3 and 15 amino acids, preferably a length of between 3 to 12 amino acids, more preferably 3 to 8 amino acids;
- (ii) comprises at least 3, preferably at least 4, at least 5 or at least 6 positively charged amino acid residues, preferably arginine residues and/or lysine residues, in particular arginine residues; and/or (iii) comprises or consists of the following amino acid sequence: RRRRRR (SEQ ID NO: 1); RRRRR (SEQ ED NO: 2), RRRR (SEQ ID NO: 3), RRR, RRRRRRR (SEQ ID NO: 4), RRRRRRRR (SEQ ID NO: 5), RRRRRRRRR (SEQ ID NO: 6), RRRRRRRRRR (SEQ ID NO 7), R RR RRRRRR (SEQ ID NO: 8), RRRRRRRRRRRR (SEQ ED NO: 9), RRRRR C (SEQ ID NO: 10); RRRRRC (SEQ ED NO: 11), RRRRC (SEQ ID NO: 12); RRRC (SEQ ID NO: 13), RRRRRRRC (SEQ ID NO: 14), R
- (iv) additionally comprises one or more amino acids selected from the group consisting of Dab, C, A, G, or K and/or
- (v) has a positive net charge of at least +2, preferably of at least +3, preferably of at least +4, preferably of at least +5, or more preferably of at least +6.
- the polypeptide comprises a C-terminal cysteine residue, wherein the carbonyl-group of said C-terminal cysteines is substituted by a carboxamide group.
- modified cysteine residue has the following structure , wherein the bond shown in the amino group is connected to the remaining amino acids of the polypeptide and the sulfur is connected to the linker if present or the antibiotic core. It is further preferred that the polypeptide consists of 3 to 10 amino acids and comprises between 3 to 8 arginine residues, preferably 3, 4, 5, 6, 7 or 8, most preferably 6. More preferably that the polypeptide consists of 4 to 8 amino acids and comprises between 3 to 8 arginine residues, preferably 3, 4, 5, 6, 7 or 8, most preferably 6. In the most preferred embodiment the polypeptide consists of 6 arginine residues.
- polypeptide comprises or consists of RRRRRR (SEQ ID NO: 1).
- polypeptide comprises or consists of CRRRRRR (SEQ ID NO: 40).
- polypeptide comprises both arginine and lysine.
- preferred peptides comprise or consist of 1 R and 3 K, 2 R and 2 K, 3 R and 1 K, 1 R and 4 K, 2 R and 3 K, 3 R and
- N- or C-terminal Cys residue facilitates coupling of the peptide.
- polypeptide further comprises a tyrosine, preferably D- tyrosine.
- a tyrosine preferably D- tyrosine.
- polypeptide of the present invention is coupled directly to the structure of the antibiotic or is coupled to a linker.
- the polypeptide is coupled to a linker.
- the antibiotic or the linker is coupled to the N- or C-terminal amino acid of the polypeptide or to the side chain of an amino acid of the polypeptide, preferably an internal amino acid of the polypeptide.
- the antibiotic of the first or the second aspect of the present invention comprises 1, 2, 3 or 4 polypeptides P p.
- the antibiotic of the first or the second aspect of the present invention comprises 1 or 2 polypeptides P P.
- the antibiotic of the first or the second aspect of the present invention comprises 1 polypeptide P p.
- the antibiotic according to the first or the second aspect of the invention comprises one polypeptide P p , which is attached to element X j of structure (I) as part of -P p or -L-P p as indicated for x of structure (I).
- the antibiotic according to the first or the second aspect of the invention comprises one polypeptide P p , which is attached to element X 2 of structure (I).
- the polypeptide P P is part of Y 9 as defined above.
- the antibiotic according to the first or the second aspect of the invention comprises one polypeptide P P , which is attached to element X 3 of structure (I).
- the polypeptide P P is part of X 14 or X 15.
- the antibiotic according to the first or the second aspect of the invention comprises one polypeptide P p , which is attached to element X 4 of structure (I) as part of -P P or -L-Pp as indicated for X 4 of structure (I).
- a polypeptide P p is attached to each of the elements X ! and X 3 of structure (I).
- the polypeptide P p is attached to element X 3 of structure (I) as part of X 14 or X 15 and the second polypeptide P p is attached element X 3 as part of -P p or -L-P p as indicated for Xi of structure (I).
- polypeptide P P is attached to element Wi of structure (P) as part of -P p or -L-P P as indicated for Wi of structure (I).
- linker is mainly involved in determining the organ distribution of the antibiotic.
- the use of a linker with a higher lipophilicity will direct the conjugate to the liver.
- the use of PEGylated linkers can achieve a prolonged retention time in the bloodstream.
- the optional linker also designated“L” when present is selected from the group consisting of: etkylenediamine, SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1 - carboxylate), succinimidyl-([N-maleimidopropionamido]-(ethyleneglycol) n )ester, wherein n is an integer between 1 to 10, preferably the linker is ethylenediamine and/or SMCC, most preferably the linker is SMCC.
- the optional linker may comprise two or more of the disclosed linkers coupled to each other.
- Non limiting examples would be a combination of ethylenediamine with SMCC or siiccinimidyl-([N-maleimidopropionamido]-(ethyleneglycol) n )ester, wherein n is an integer between 1 to 10.
- the optional linker also designated“L” when present is selected from the group consisting of:
- n', f for each occurrence are independently are integer from 1 to 10, 2 to 9, 3 to 8 or are optionally 0;
- n" and p" for each occurrence are independently are 0 or 1 ;
- X is a bond to P p or a bond to a cysteine, preferably the sulphur group of said cysteine, wherein the cysteine is bound to P p , optionally the carbonyl- group of said cysteine is substituted by a carboxamide group;
- X is selected from a maleimido group, a haloacetyl group or SR 37 , wherein R 37 has the same definition as above;
- A" is an amino acid selected from glycine, alanine, leucine, valine, lysine, eitmlline and glutamate or a polypeptide containing between 2 to 20 amino acid units;
- R-20, R 2I , R-22, R 23 , R2 % R 25 , R 26 , and R 27 are the same or different and are H or a linear or branched alkyl having from 1 to 5 carbon atoms;
- R 2 9 and R 30 are the same or different and are H or alkyl from 1 to 5 carbon atoms;
- R 33 is H or linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 12 carbon atoms, a polyethylene glycol unit— (OCH 2 CH 2 ) n , or R 33 is— COR 34 ,— CSR 34 ,— SOR 34 , or— SG 2 R 34, wherein R 34 is H or linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 20 carbon atoms or, a polyethylene glycol unit— (OCH 2 CH 2 ) n ; and
- R40 and R 4J is optionally a negatively or positively charged functional group and the other is H or alkyl, alkenyl, alkynyl having 1 to 4 carbon atoms.
- a minimal inhibitory concentration that is at least 50% lower than the MIC of the respective antibiotic without the coupled polypeptide; preferably for antibiotics with a vancomycin core of 8 mg/L or less against E. faecium VanA UL602570, E. faecium VanA UL407074, E.faecalis VanO ATCC292I2, E.faecalis VanB SC413687, E.faecalis VanB ATCC 51299, E. faecium VanB UL405955, E. casseliflavus VanC ATCC 700327 and E. gallinamm VanC AL405773;
- MIC minimal inhibitory concentration
- PBMCs peripheral blood mononuclear cells
- the antibiotics have one or more of the following properties: (i) a minimal inhibitory concentration (MIC) that is at least 50% lower than the MIC of the respective antibiotic without the coupled polypeptide; preferably for antibiotics with a vancomycin core of 8 mg/L or less against E. faeciurn VanA UL602570, E. faecium VanA UL407074, E. faeealis VanO ATCC29212, E. faecalis VanB SC413687, E.faecalis VanB ATCC 51299, E. faecium VanB UL405955, E. casseliflavus VanC ATCC 700327 and E. gallinarum VanC AL405773;
- MIC minimal inhibitory concentration
- PBMCs peripheral blood mononuclear cells
- a cytotoxicity against human liver cells of less than 10% at the MIC, preferably less than 10% cytotoxicity at 64 pg/ml;
- a cytotoxicity against human kidney cells of less than 10% at the MIC, preferably less than 10% cytotoxicity at 64 pg/ml.
- the antibiotic sensitivity which refers to the resistance of bacteria against an antibacterial compound is determined as known in the art, for example by in vitro cultivation of isolated bacteria in the presence or absence of different antibiotics and different concentrations thereof. Bacterial strains can be defined regarding their antibiotic resistance by an antibiogram, which commonly refer to the MIC of the tested antibiotics. Antibiotic sensitivity can be measured by a Vitek-2 system (bioMerieux) according to the manufacturer’s instructions. Determination of resistance gene is performed by PCR as described in Klein et al. (Journal of Medical Microbiology (2012), 61, 323-331).
- Biodistribution e.g. liver, kidney etc. accumulation
- Bioconjugate chemistry 27.4 (2016): 1050-1057 can be measured as known in the art, for example by biodistribution studies as described in (Wischnjow et al., Bioconjugate chemistry 27.4 (2016): 1050-1057).
- the antibiotics of the first or second aspect is for use in the treatment or prophylaxis of a bacterial infection.
- the bacterial infection is with a bacterium selected from the group consisting of a gram negative and gram positive bacterium, preferably a vancomycin-resistant bacteria, in particular Enterococci, Staphylococci, or Streptococci.
- the bacterial infection is with a multiple drug resistant bacterium (MRSA), e.g. VRE, preferably Staphylococci, E.faecium, E.faecalis, 01 ⁇ . gallinarum.
- MRSA multiple drug resistant bacterium
- the antibiotic is used in combination with one or more antibiotics selected from the group consisting of glycopeptides, tetracyclines, aminoglycosides, and cephalosporines.
- V c corresponds to substituent X j in structure (I), V v to substituent X 2 , V N to substituent X 3 and V R to substituent X4.
- BB-2041 [Scheme 2] was synthesized from vancomycin ⁇ HC1, formaldehyde and ethylene diamine according to Long et al. [19] and purified by preparative HPLC afterwards.
- BB-2057 was synthesized according to Griffin et al. [21] using vancomycin HC1 and N-(9- fluorenthoxycarbonyl)glycinal and purified by preparative HPLC (see scheme 6).
- vancomycin ⁇ HC1 149 mg; 0.1 mmol
- DIPEA N-Ethyl-N-(propan-2-yl)propan-2-amine
- ethylene diamine (10 m ⁇ ; 0.149 mmol) was added followed by a solution of Benzotriazol-l-ol (HOBt) (14.8 mg; 0.11 mmol) and PyAOP ((7-Azabenzotriazol-l- yloxy)tripyrrolidinophosphonium hexafluorophosphate) (58 mg; 0.11 mmol) in DMF (0.5 ml). After 2 hours, the mixture was purified by preparative HPLC and the purified fraction was lyophilized. The yield of the reaction was 97.5 mg.
- HOBt Benzotriazol-l-ol
- PyAOP ((7-Azabenzotriazol-l- yloxy)tripyrrolidinophosphonium hexafluorophosphate)
- the peptides were synthesized using Fmoc-solid phase synthesis as described previously by Brings et al. [22] Therefore, a rink amid resin was loaded with 0.74 mmol cysteine per g resin. After automated coupling, using an Applied Biosystems 433 A synthesizer, the resin was washed with DCM and MP. The cleavage of the peptide was performed in a mixture of TFA/H 2 0/TIS at a ratio of 90/5/5 for 4 hours with a following precipitation in diethyl ether and a centrifugation (3000 rpm, 5 min, two times).
- the purification of the peptides was performed on a Gilson 321 High-Performance Liquid chromatography (HPLC) system with a Reprosil Gold 120 C18 4 pm 150 x 120 mm column (Dr. Maisch, Ammerbuch, Germany).
- HPLC/MS using a Thermo Fisher Exactive Orbitrap System equipped with a Cl 8 column, (Hypersil Gold aQ, Thermo Scientific, USA) was used.
- Example 8 Coupling of the peptide to vancomycin-linker-con j ugate
- the product was mixed with one equivalent of Atto-488 (Atto-Tec, Siegen Germany) in a Na 2 C0 3 -buffered solution (pH > 9). The mixture was shaken overnight at room temperature.
- the purification was performed by preparative HPLC.
- MICs were determined by microdilution according to CLSI guidelines [23, 24]. Briefly, Cation-adjusted Mueller-Hinton-Broth and vancomycin (potency 99.1%) were purchased from Sigma-Aldrich (Steinheim, Germany). For all tests polypropylene 96well plates (Sigma-Aldricli, Stein eim, Germany) were used. Antimicrobial substances were dissolved in water. For vancomycin-conjugates different concentrations were used. All other antibiotic-conjugates were used in dilutions ranging from 64 pg/ml to 31.25 ng/ml.
- Example 11 Staining protocol for viability and cell membrane permeability of Bacillus megaterium
- DAPI a membrane permeable dye to stain all bacteria (living and dead) by binding double-stranded DNA [26]
- PI propidium iodide
- PI is a dye for staining dead bacteria with damaged membranes (Lecoeur, Exp Cell Res. 2002;277:1-14).
- the cell suspension was mixed with 100 m ⁇ of the corresponding conjugate (FU002) in a 5x MIC concentration and 0.42 mg of the Atto-labeled conjugate. After 30 min incubation at 30 °C only PI was added and the suspension was incubated for further 10 min. The following steps were performed as described above.
- a 1 niM stock solution in phosphate buffer/ dimethyl sulfoxide (DMSO) was prepared as described previously by Uhl et al. [27].
- cytotoxic potency/activity towards human cells was assessed in a colorimetric viability assay.
- human PBMCs, HepG2 liver cells or HEK-293 kidney cells were seeded into 96-well microtiter plates (Costar ® , Coming, Tewksbury, MA, USA) at 2 x 10 4 cells/well and cultured overnight (18-24 h) in a humidified atmosphere at 37 °C and 5% C0 2.
- the R6C conjugate and mitomycin c as control were added at final concentrations of 0.25 pg/mL up to 128 pg/mL in 2-fold dilution steps.
- Example 14 Structural analysis of FU002
- Radiolabeling of the compounds was performed according to the instructions of example 12, with the exception that the isotope 124 I was used.
- the animal trials were approved by the Animal Care and Use commitees at the Regienmgsprasidium Düsseldorf, Germany.
- Adult, female, Wistar rats (200 - 250 g) were purchased from Janvier Labs (Le Genest-Saint-Isle, France).
- the animals were anaesthetized by isoflurane inhalation and appropriate amounts of the 124 I-labelled peptides, dissolved in 100 m ⁇ of 0.9% NaCl were injected into the tail vein.
- PET-imaging was performed on an Inveon small animal PET scanner (Siemens). Therefore, the animals were sacrificed 10 min after injection of the radiolabeled compounds and images were taken immediately.
- Example 16 MIC of the daptomycin conjugate FU004
- daptomycin conjugates The synthesis of daptomycin conjugates is performed analogous to the synthesis of the vancomycin conjugates disclosed herein.
- the minimal inhibitory concentration of daptomycin and a daptomycin-R6-Conjugate (FU004; see Fig. 26) on daptomycin sensitive (HG001 SA) and daptomycin-resistant bacteria (HG001 DRSA) was determined. No difference in MIC between daptomycin-sensitive (HG001 SA) and daptomycin-resistant bacteria (HG001 DRSA) is observed for FU004 (see Table 2). In contrast, the MIC of daptomycin itself is strongly increased on daptomycin resistant bacteria (HG001 DRSA) as expected.
- FU004 accumulates predominantly in the liver (Fig. 27; Ih) and shows elimination via the intestines and kidneys starting 1 h post administration. Daptomycin accumulates in the kidneys (Fig. 28) and shows an elimination starting 1 h post administration.
- Example 18 In vivo toxicity of conjugate FU002 and vancomycin
- the in vivo toxicity of FU002 and vancomycin was determined in CD-I female mice. The study included three treatment groups: (1): 0.9% NaCl (10 ml//kg; iv); (2) vancomycin (30 mg/kg; iv) and (3) vancomycin conjugate FU002 (56.4 mg/kg; iv). Respective treatment was applied twice daily for the first 5 days. Total duration was 14 days.
- An antibiotic comprising an antibiotic core and at least one polypeptide of a length of 2 to 20 amino acids, preferably of a length of 2 to 12 amino acids, wherein the N-terminus of the polypeptide is not attached to a lipophilic group and the polypeptide is positively charged and optionally a linker connecting the antibiotic core and the polypeptide, wherein the antibiotic core is selected from the group consisting of a glycopeptide antibiotic; a cyclic lipopeptide antibiotic; a B-lactam antibiotic, a cephalosporine antibiotic; and an oxazolidinone antibiotic; preferably a glycopeptide antibiotic and a cyclic lipopeptide antibiotic.
- glycopeptide antibiotic is selected from the group consisting of vancomycin, teicoplanin, A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850, A84575, AB-65, actaplanin, actinoidin, ardacin, avoparcin, azureomycin, balhimycin, chloroorientiein, chloropolysporin, dalbavancin, decaplanin, N- demethylvancomycin, eremomycin, galacardin, helvecardin, izupeptin, kibdelin, LL- AM374, mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, orenticin, parvodicin, ristoract
- cyclic lipopeptide antibiotic is selected from the group consisting of daptomycin dalbavancin, oritavancin and telavancin;
- b-lactam antibiotic is selected from the group consisting of penicillin, amoxicillin, and ampicillin;
- cephalosprine antibiotic is selected from the group consisting of cefazolin, cefadroxil, cephalexin, cefuroxim, cefotiam, cefaclor, cefuroxim, loracarbef, cefixim, cefpodoxim, ceftibuten, cefotaxim, ceftriaxon, ceftazidim, cefepim ceftobiprol, ceftolozan, ceftarolin; and
- P p is a polypeptide of a length of 2 to 40, preferably of 2 to 20, amino acids;
- L is a linker
- u is an integer ranging from 1 to 4, preferably 2 to 3, r is selected from 0 or 1, s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4, t is an integer ranging from 2 to 18, preferably 4 to 16,
- X 2 is selected from structure (
- Y t is selected from -H, -OH, and -NH-Y 9 ,
- Y 2 is selected from -H and -C3 ⁇ 4,
- Y 6 is selected from -H, and -0-Y 8 ,
- Y 8 is a substituted tetrahydrofuranyl, preferably a substituted tetrahydrofuranyl-3-4-diol, more preferably 2-(hydroxymethyl)tetrahydrofuranyl-3-3- diol,
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl or a C n alkyl, or;
- a branched or unbranched C 3 to C l9 alkyl or alkenyl preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to Ci7 alkyl, most preferably a C 9 to Cn alkyl.
- X 3 is selected from -NX I4 -CH 3 and -NH-Xn,
- X4 is selected from -H, -(CH 2 ) n -NH -(CH 2 ) n -P P -(CH 2 ) n -NH-(CH 2 ) ⁇ -L-P P ; -(CH 2 ) n -NH- P p , -(CH 2 ) n -NH-L-P P -P p , -L-P p and a substituted phosphonic acid, preferably substituted methylamino-phosphonic acid, wherein n is an integer ranging from 1 to 4, preferably 2 to 3, wherein n’ is an integer ranging from 1 to 4, preferably 2 to 3;
- X 5 is selected from -H, and substituted tetrahydropyranyl, preferably amino-methyl- hydroxy-tetrahydropyranyl or (dihydroxy-hy dr oxymethy l-tetrahydropyran)-acetamide ;
- C b is selected from -H, -Cl, -F, -Br, and -I;
- X 7 is selected from -H, -Cl, -F, -Br, and -I;
- X 8 is selected from -H and -O-Y 10 ,
- Y 10 is selected from -H or substituted tetrahydropyranyl, preferably hydroxymethyl-trihydroxy-tetrahydropyranyl;
- X9 is selected from -H and substituted tetrahydropyranyl, preferably hydroxymethyl— friliydroxy-tetrahydropyranyl or (methylacetate)-trihydroxytetrahydro-pyranyl;
- X10 is selected from acetamide and substituted or unsubstituted phenyl, preferably phenyl or halobenzyl, and X n is selected from C 3 to C 6 alkyl, preferably a C alkyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or
- X 10 and X u are linked by a unsubstituted or substituted diphenyl ether, preferably a substituted or unsubstituted hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo-hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy- phenyl;
- X 12 is selected from -CH 2 -OH, -COOH, -0-Y n ,
- Y n is substituted tetrahydropyranyl, preferably methyltrihydroxytetrahydropyranyl
- antibiotic of (I) comprises at least one P p ;
- Wi is selected from -P p or -L-P p.
- Xi is selected from -OH,
- u is an integer ranging from 1 to 4, preferably 2 to 3, wherein P p is said polypeptide and L is said linker, with the proviso that the N-terminus of P p is preferably not attached to a lipophilic group;
- X 2 is selected from structure (PI), or -NH-CO-Y 3 ,
- Y 3 is selected from -H, -OH,
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a C 9 alkenyl oraC n alkyl; or (ii) a branched or unbranched C 3 to C 19 alkyl or alkenyl, preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C
- Y 6 is selected from -H or
- X 3 is selected from -NX I4 -C3 ⁇ 4 or -NH-X 15 ,
- X 14 is selected from -H, -P p or -L-P p , -(CH 2 ) U -(NH)-P p , -(C3 ⁇ 4) U -(NH)-L-
- X 15 is selected from -H, -P p or -L-P p , -(CH 2 ) U -(NH)-P p , -(CH 2 ) U -(NH)-L-
- P p wherein u is an integer ranging from 1 to 4, preferably 2 to 3, wherein P p is said polypeptide and L is said linker;
- X 4 is selected from -H, -P or -L-Pp, wherein P P is said polypeptide and L is said linker:
- X 5 is selected from
- g is selected from -H, -Cl
- X 7 is selected from -H, -Cl
- Xs is selected from -OH, -H, or
- X 9 is selected from -H or , wherein Y 7 is selected from -H or-CO-C3 ⁇ 4;
- X 10 is selected from , wherein Y 5 is selected from -H or -Cl, and X n is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl,
- Xio and Xu are linked by whereby Y 4 is selected from
- X12 is selected from -C3 ⁇ 4-OH, -COOH or The antibiotic of any one of items 3 and 4, wherein the positively charged polypeptide comprises 2 to 30, preferably 2 to 15, lysine and/or arginine residues.
- u is an integer ranging from 1 to 4, preferably 2 to 3, r is selected from 0 or 1
- s is an integer ranging from 1 to 6, preferably 2 to 4, more preferably 3 to 4
- t is an integer ranging from 4 to 16, wherein P p is said polypeptide and L is said linker, with the provisio that the N- terminus of P p is preferably not attached to a lipophilic group;
- X 2 is selected from structure (PI), or -NH-CO-Y 3 ,
- Y 1 is selected from -H, -OH, -NH-Y 3 ⁇ 4
- Y 6 is selected from -H, -0-Y 8 ,
- Y 8 is a substituted tetrahydrofiiranyl, preferably a substituted tetrahydrofuranyl-3-4-diol, more preferably 2-
- Y 3 is (i) a branched or unbranched C 8 to C 12 alkyl or alkenyl, preferably a
- a branched or unbranched C 3 to C 19 alkyl or alkenyl preferably a branched or unbranched C 5 to C 17 alkyl or alkenyl, more preferably a C 5 to C 17 alkyl, most preferably a C 9 to Cu alkyl;
- X 3 is selected from -NX 14 -CH 3 or -NH-X 15 ,
- X 4 i s selected from -H, - ⁇ CH 2 ) n -NH -(C3 ⁇ 4V-P P -(CH 2 ) n -NH-(CH 2 ) n .-L-P P ; -(CH 2 ) n - NH-P P , -(CH 2 ) n -NH-L-Pp -P p , -L-P p or a substituted phosphonic acid, preferably substituted methylamino-phosphonic acid, herein n is an integer ranging from 1 to 4, preferably 2 to 3, wherein o’ is an integer ranging from 1 to 4, preferably 2 to 3; wherein P P is said polypeptide and L is said linker; X 5 is selected from -H, or substituted tetrabydropyranyl, preferably amino-methyl- hydroxy-tetrahydropyranyl or (dihydroxy-hydroxymethyl-tetrahydropyran)- acet
- 3 ⁇ 4 is selected from -H, -Cl, -F, -Br, -I;
- X 7 is selected from -H, -Cl, -F, -Br, -I;
- X 8 is selected from -H or -O-Y 10 .
- Y 10 is selected from -H or substituted tetrabydropyranyl, preferably hydroxymethyl-trihydroxy-tetrahydropyranyl;
- X 9 is selected from -H or substituted tetrahydropyranyl, preferably hydroxymethyl— trihydroxy-tetrahydropyranyl or (methylacetate)-trihydroxytetrahydro-pyranyl;
- X 10 is selected from acetamide or substituted or unsubstituted phenyl, preferably phenyl orhalobenzyl, and Xu is selected from C 3 to C 6 alkyl, preferably a C 4 alkyl, substituted phenyl, preferably methyl-trihydroxy-tetrahydropyranyl substituted phenyl; or
- X 10 and X u are linked by a substituted phenyl ether, preferably a substituted or unsubstituted hydroxyphenoxy-phenyl, more preferably hydroxyphenoxy-phenyl, halo-hydroxyphenoxy-phenyl or methyl-hydroxyphenoxy-phenyl;
- X 12 is selected from -C3 ⁇ 4-OH, -COOH, -0-U p ,
- Y u is substituted tetrahydropyranyl, preferably methyltrihydroxytetrahydropyranyl
- Wi is selected from -P P or -L-P P , wherein P P is said polypeptide and L is said linker.
- (i) has a length of between 3 and 15 amino acids, preferably a length of between 3 to 12 amino acids; and/or (ii) comprises at least 3, preferably at least 4, at least 5 or at least 6 arginine residues; and/or
- (iii) comprises or consists of the following amino acid sequence: RRRRRR (SEQ ID NO:
- RRRRR SEQ ED NO: 2
- RRRR SEQ ID NO: 3
- RRR RRRRRRRRR
- SEQ ID NO: 4 RRRRRRRRRR
- SEQ ID NO: 5 RRRRRRRRR
- SEQ ED NO: 6 RRRRRRRRRRRR
- RRRRRRRRRR SEQ ID NO 7
- RRRRRRRRRRRRR SEQ ID NO: 8
- RRRRRRRRRRRR SEQ ID NO: 9
- RRRRRRC SEQ ID NO: 10
- RRRRRC SEQ ID NO: 11
- RRRRC SEQ ID NO: 12
- RRRC SEQ ID NO: 13
- RRRRRRRC SEQ ID NO: 14
- RRRRRRRRC SEQ ID NO: 15
- RRRRRRRRRC SEQ ID NO: 16
- RRRRRRRRRRC SEQ ID NO 17
- RRRRRRRRRRRC SEQ ID NO: 18
- RRRRRRRRRRRRC SEQ ED NO: 19
- RRK RKR
- (iv) additionally, comprises one or more amino acids selected from the group consisting of Dab, C, A, G, or K; and/or
- (v) has a positive net charge of at least +2, preferably of at least +3, preferably of at least +4, preferably of at least +5, or more preferably of at least +6.
- n', p, q, in', n', t' for each occurrence are independently integer from 1 to 10, 2 to 9, 3 to 8 or are optionally 0;
- n" and p" for each occurrence independently are 0 or 1 ;
- X" is a bond to P p , or a bond to a cysteine, preferably the sulphur group of said cysteine, wherein the cysteine is bound to P p , optionally the carbonyl-group of said cysteine is substituted by a carboxamide group;
- Y" is absent or is selected from O, S, S— S or NR 32 , wherein R 32 , for each occurrence, is independently selected from the group consisting of— H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit— (CH 2 CH 2 0)n— Rc, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P, or
- X is selected from a maleimido group, a haloacetyl group or SR37, wherein R 37 has the same definition as above;
- A" is an amino acid selected from glycine, alanine, leucine, valine, lysine, citralline and glutamate or a polypeptide containing between 2 to 20 amino acid units;
- R 20 , R 2I , R 22 , 23 , R 24; R 25 , R 26 and R 27 are the same or different and are H or a linear or branched alkyl having from 1 to 5 carbon atoms;
- R 29 and R 30 are the same or different and are H or alkyl from 1 to 5 carbon atoms;
- R 33 is H or linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 12 carbon atoms, a polyethylene glycol unit— (OCH 2 CH 2 ) n , or R 33 is— COR 34 ,— CSR 34 ,— SOR 34 , or — S0 2 R 34 , wherein R 34 is H or linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 20 carbon atoms or, a polyethylene glycol unit— (OCH 2 CH 2 ) n ; and
- R 40 and R 41 is optionally a negatively or positively charged functional group and the other is H or alkyl, alkenyl, alkynyl having 1 to 4 carbon atoms; or
- n is an integer between 1 to 10, preferably the linker is ethylenddiamine or SMCC.
- a minimal inhibitory concentration (MIC) that is at least 50% lower than the MIC of the respective antibiotic without the coupled polypeptide; preferably for conjugates of vancomycin of 8 mg/L or less against E. faecium VanA UL602570, E. faecium VanA UL407074, E. faecalis VanO ATCC29212, E. faecalis VanB SC413687, E. faecalis VanB ATCC 51299, E.faecium VanB UL405955, E. casseliflavus VanC ATCC 700327 and E. gallinamm VanC AL40 773;
- MIC minimal inhibitory concentration
- PBMCs peripheral blood mononuclear cells
- a cytotoxicity against human liver cells of less than 10% at the MIC, preferably less than 10% cytotoxicity at 64pg/ml;
- a cytotoxicity against human kidney cells of less than 10% at the MIC, preferably less than 10% cytotoxicity at 64pg/ml.
- bacterial infection is with a bacterium selected from the group consisting of a gram negative and gram positive bacterium, preferably a vancomycin-resistant bacteria, in particular Enterococci , Staphylococci, or Streptococci , wherein the bacterial infection is preferably with a multiple drug resistant bacterium (MRS A), preferably Staphylococci, E.faecium , E. faecalis, or E. gallinamm.
- MRS A multiple drug resistant bacterium
- An antibiotic of any one of items 1 to 11 for use as a medicament 15.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18192564 | 2018-09-04 | ||
PCT/EP2019/073518 WO2020049015A2 (en) | 2018-09-04 | 2019-09-04 | Improved polypeptide coupled antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3846854A2 true EP3846854A2 (en) | 2021-07-14 |
Family
ID=63517683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19769720.4A Pending EP3846854A2 (en) | 2018-09-04 | 2019-09-04 | Improved polypeptide coupled antibiotics |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3846854A2 (en) |
WO (1) | WO2020049015A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111307775A (en) * | 2020-03-27 | 2020-06-19 | 郑州鲲鹏健康科技有限公司 | Method for detecting PBMC activity under in-vitro 3D culture condition by applying resazurin reagent |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011019839A2 (en) * | 2009-08-12 | 2011-02-17 | The Medicines Company | Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
-
2019
- 2019-09-04 EP EP19769720.4A patent/EP3846854A2/en active Pending
- 2019-09-04 WO PCT/EP2019/073518 patent/WO2020049015A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020049015A2 (en) | 2020-03-12 |
WO2020049015A3 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100469788C (en) | Glycopeptide Phosphonate Derivatives | |
KR100665204B1 (en) | Glycopeptide Derivatives and Pharmaceutical Compositions Comprising the Same | |
EP1005356B1 (en) | Novel antibacterial agents | |
KR101730680B1 (en) | Therapeutic peptides | |
CN102348718B (en) | Deoxyactagardine derivatives | |
RU2506272C2 (en) | Lantibiotic carboxyamide derivatives with enhanced antibacterial activity | |
Funabashi et al. | A new anti-MRSA dipeptide, TAN-1057 A | |
US11046730B2 (en) | Antimicrobial compositions | |
KR20190093600A (en) | Antibacterial peptide | |
JP6017534B2 (en) | Method for producing antifungal agent | |
CA3103619A1 (en) | Synthesis of echinocandin antifungal agent | |
JPH10506650A (en) | Anhydrous 7-([1α, 5α, 6α] -6-amino-3-azabicyclo [3.1.0] hex-3-yl) -6-fluoro-1- (2,4-difluorophenyl) -1, Novel crystalline form of 4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylic acid methanesulfonate | |
EP3846854A2 (en) | Improved polypeptide coupled antibiotics | |
AU2005298863B2 (en) | Purification of glycopeptides | |
US20100216699A1 (en) | Semi-synthetic glycopeptides having antibacterial activity | |
CN105085636B (en) | Vancomycin derivatives, preparation method thereof and application thereof in antibiosis | |
US20250011366A1 (en) | Prodrugs of Antibiotic Teixobactin | |
Tan et al. | Chemistry and biology of glycopeptides with antibiotic activity | |
EP0505735A1 (en) | Antibiotic A 40926 ester derivatives | |
CN109053864B (en) | Method for preparing oritavancin | |
CN106317206B (en) | Norvancomycin dimer derivative and preparation method and medicinal application thereof | |
WO2023023312A1 (en) | Tunable polymeric nanoparticles for targeted and sustained delivery of glycopeptide antibiotics | |
WO2023146255A1 (en) | Peptide transporter including hydrophobic structure that binds to albumin | |
IE911798A1 (en) | Use of C63 derivatives of 34-de (acetylglucosaminyl)-34-deoxy-teicoplanin against bacteria resistant to glycopeptide antibiotics | |
CN120484061A (en) | Orotate crystal of octreotide and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210324 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITAET HEIDELBERG |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DOMHAN, CORNELIUS Inventor name: UHL, PHILIPP Inventor name: UMSTAETTER, FLORIAN Inventor name: MIER, WALTER |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231016 |